Epithelial ovarian cancer is the fourth biggest cause of cancer ... In order to improve the efficacy and reduce the toxicity of first-line chemotherapy, more than 10,000 women have been involved ...

Patients and Methods: A total of 320 patients with AOC were centrally screened for HER2 status (243 patients in fi rst line ... [FISH] positive) ovarian cancer progressing under taxane/carboplatin ...

18, 2024 — Scientists have generated human stem cell models which contain notochord ... lifetime could have implications ... How Breast Cancer Cells Survive in Bone Marrow After Remission ...

Jan. 3, 2025 — Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, ... Enzyme Promoting Tumor Growth ...

Results of a comprehensive analysis refute assumptions that a key immune checkpoint receptor functions the same in rodents and humans Since its discovery in the 1990s, “programmed cell death protein 1 ...

The results suggest that AZ and Daiichi Sankyo could be in line for a second big win for a cancer ADC to follow Enhertu (trastuzumab deruxtecan), their HER2-directed drug which has just claimed a ...

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...

Two anti-transferrin receptor (TfR) nanobodies, V H H123 specific for mouse TfR and V H H188 specific for human TfR (huTfR) were used to track transplants non-invasively by PET/CT in mouse models, ...

More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

Trying to force progress? The more you push, the more pushback you’ll receive as the moon clashes with Mars! Frustration over a botched timeline inspires you to take matters into your own hands.

With today’s Aries moon activating your sense of authority, you could be tempted to pull rank and call the shots. Yes, you’ve done more than your share of hard work, but what makes you think ...

which included two phase 3 trials - KeyVibe-003 and KeyVibe-007 - in patients with non-small cell lung cancer (NSCLC). MSD, known as Merck & Co in the US and Canada, said the studies' independent ...